Search

The commonly used criteria for SAPHO syndrome were proposed by Kahn in 1997 and revised in 2003:[1] (1) bone-joint involvement associated with PPP and psoriasis vulgaris; (2) bone-joint involvement associated with SA; (3) isolated sterile hyperostosis/osteitis; and (4) chronic recurrent multifocal osteomyelitis (children). Upadacitinib effectively relieved bone pain and skin damage in patients, and no significant adverse effects were found; thus, it may be a potential treatment option for SAPHO syndrome. Keywords: autoinflammatory disease; SAPHO syndrome; treatment option; upadacitinib EN autoinflammatory disease SAPHO syndrome treatment option upadacitinib 2335 2337 3 11/03/23 20231101 NES 231101 SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) is a rare autoinflammatory disease which may manifest clinically as aseptic osteomyelitis and aseptic joint inflammation, with or without cutaneous manifestations.[1] Osteoarticular symptoms occur mainly in the anterior chest wall (ACW) and may also involve the spine and peripheral joints. [Extracted from the article]

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disease with osteoarticular and cutaneous involvements as its main manifestations. Acne conglobata as a severe acne form may affect adolescent patients. Tumor necrosis factor inhibitors are usually used as a second-line therapy for refractory SAPHO syndrome and has been reported to treat acne conglobata successfully. We herein report three cases of adolescent patients with SAPHO syndrome associated with acne conglobata who were successfully treated with TNFi therapy. [ABSTRACT FROM AUTHOR]

Keywords: leflunomide; nail; SAPHO syndrome EN leflunomide nail SAPHO syndrome 156 157 2 02/17/23 20230201 NES 230201 Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome is a rare autoimmune disease characterized by osteoarticular and dermatological manifestations.[1] Nail involvement is a common manifestation of SAPHO syndrome and often disrupts patients' daily activities and quality of life. We herein describe a patient with SAPHO syndrome with nail involvement that exhibited a complete response to single-agent treatment with leflunomide. [Extracted from the article]